McKesson stock

MCK · NYSE · USD

Compare McKesson
$1,091.67Change from previous close: −1.21%Absolute change: −$13.37

Close · November 17, 2026

Price history

+27.87% over the period

1 year: from $855.23 (November 17, 2025) to $1,093.56 (November 17, 2026), +27.87%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$1,093.56
October 30, 2026$994.58
September 30, 2026$853.81
August 31, 2026$885.32
July 31, 2026$856.19
June 30, 2026$755.60
May 29, 2026$742.44
April 30, 2026$815.20
March 31, 2026$865.36
February 27, 2026$987.37
January 30, 2026$831.21
December 31, 2025$820.29
November 28, 2025$881.12
November 17, 2025$855.23

At a glance

TickerLandia's take on McKesson

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$723.68
52-wk high$1,121.50

−2.66% from the 52-week high

Analysts · 16 analysts

Average target$1,144.29+4.82% vs. price

Buy 13 · Hold 3 · Sell 0 · Buy

TickerLandia Fingerprint: McKesson

Compared with similar companies: very strong momentum.

Financials and price compared with 11 companies in the medical distribution industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

McKesson is pricier than in the past and in line with similar companies

On the latest fiscal year's earnings (2026), McKesson's P/E today is 28.5, above the median of its last 7 fiscal years (24.0; between 6.52 and 42.3 from 2017 to 2026). McKesson's P/E (trailing 12 months): 28.5, in line with the median of a group of 11 similar companies (28.2).

P/E compared with its history

Compared with 11 similar companies

McKesson's metrics compared with similar companies
MetricMcKessonPosition in the groupBand
P/E (trailing 12 months)28.5Middle
Forward P/E21.1Middle
Operating margin1.6%Low
EV/EBITDA18.5High
Net margin1.1%Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: McKesson. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$110.96B

Latest quarter · Q3 2026

Net income

$1.22B

Latest quarter · Q3 2026

Quarterly net margin

1.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$127.58B
P/E
28.5
EPS
$38.77
Volume
720.28K
Daily trading
€665.43M
Dividend yield
0.31%

How McKesson is changing

All results
  • Revenue grew 11.1% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 137% of net income

  • Shares outstanding down 22.7% in 5 years

Returns

McKesson returns with dividends

$1,000 invested in McKesson 5 years ago, on November 17, 2021, would be worth $5,014 today with dividends reinvested: +401.36% in total, +38.05% per year. On price alone it would be $4,886 (+388.59%).

PeriodMcKessonS&P 500$1,000 becomes
1 month+8.23%−3.17%$1,082
6 months+43.53%+0.11%$1,435
Year to date+33.31%+8.34%$1,333
1 year+28.37%+11.15%$1,284
3 years+146.13%+64.30%$2,461
5 years+401.36%+58.18%$5,014
10 years+734.20%+239.10%$8,342

Over the last 6 months it has done better than 84% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

McKesson: technical analysis

McKesson is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.2% below its all-time closing high ($1,105.04, November 16, 2026).

Trend
Upward
RSI (14 sessions)
70
Between 30 and 70
vs 200-session average
+24.50%

Support and resistance

Price areas where McKesson has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$1,091.67
  3. Support$971.93−10.97%2 touches, last on February 6, 2026
  4. Support$957.00−12.34%2 touches, last on October 28, 2026
  5. Support$909.09−16.73%4 touches, last on September 23, 2026

Volatility and risk

Over the last year it has often moved in the opposite direction to the S&P 500.

Beta (1 year) vs S&P 500
−0.16
Volatility (60 sessions, annualised)
27.5%
Largest fall in the last year
−27.17%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

McKesson: seasonality

Average monthly price change over 32 years

+2.1%Jan+0.3%Feb+0.7%Mar+0.6%Apr+4.9%May+2.1%Jun+1.2%Jul−0.5%Aug+0.4%Sep−0.5%Oct+5.2%Nov+1.2%Dec

Over the last 32 years, the strongest month for McKesson has been November: +5.18% on average, positive in 22 years out of 31. The weakest has been October: −0.54% on average, positive in 17 years out of 32.

Show chart data
MonthAverageMedianPositive years
January+2.06%+3.02%22 of 32
February+0.32%+0.28%16 of 32
March+0.70%+0.39%16 of 32
April+0.57%+0.82%18 of 32
May+4.91%+6.18%25 of 32
June+2.06%+1.33%18 of 32
July+1.21%−0.47%16 of 32
August−0.48%−0.17%16 of 32
September+0.39%+0.74%16 of 32
October−0.54%+2.59%17 of 32
November+5.18%+4.27%22 of 31
December+1.23%−0.16%16 of 32

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

McKesson and its competitors

Founded in 1833 and headquartered in Irving, Texas, the group works across the healthcare chain in the United States and in several countries abroad. Its activities are organized into four segments, covering pharmacy distribution, oncology and multispecialty care, prescription technology and medical-surgical solutions. The products it handles include branded and generic medicines, specialty and biosimilar drugs, over-the-counter items and vaccines, which it delivers to retail pharmacies, hospitals, long-term care facilities, clinics and other institutions.

Headquarters
Irving, United States
Employees
41,600
Founded
1833
Chief executive
Brian Tyler
McKesson and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
McKessonMCK$127.58B1.6%28.5+43.53%
CencoraCOR$68.11B1.4%20.0+36.03%
Cardinal HealthCAH$64.97B1.3%36.4+43.06%
Henry ScheinHSIC$9.17B5.8%22.7+14.05%
Sigma HealthcareSIG$22.55B9.2%48.3+1.40%
Sinopharm Group Ltd H1099$6.68B3.0%6.51−5.65%

Same industry or related industries, similar size. Compare McKesson with its competitors · Full profile